TY - JOUR
T1 - Molecular testing in lung cancer
T2 - Where to draw the line?
AU - Halmos, Balazs
N1 - Funding Information:
Accepted for publication February 22, 2018. Published as an Early Online Release April 6, 2018. From the Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. Dr Halmos receives research funding from Merck, Mirati, Astra-Zeneca, Boehringer-Ingelheim, Pfizer, Takeda, and Eli Lilly. Additionally, he consults with Foundation Medicine, Guardant Health360, Pfizer, Eli Lilly, Genentech, Astra-Zeneca, Novartis, Boehringer-Ingelheim, and Takeda. doi: 10.5858/arpa.2018-0060-ED Corresponding author: Balazs Halmos, MD, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Rd, Bronx, NY 10461 (email: [email protected]).
PY - 2018/7
Y1 - 2018/7
UR - https://www.scopus.com/pages/publications/85049143680
UR - https://www.scopus.com/pages/publications/85049143680#tab=citedBy
U2 - 10.5858/arpa.2018-0060-ED
DO - 10.5858/arpa.2018-0060-ED
M3 - Comment/debate
C2 - 29624077
AN - SCOPUS:85049143680
SN - 0003-9985
VL - 142
SP - 787
EP - 789
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 7
ER -
